KinaSense develops products for testing new cancer drugs in the pre-clinical and clinical phases of drug discovery. We strive to be on the forefront of precision medicine by developing next generation diagnostic products for personalizing cancer patient care.
Tyrosine kinase inhibitors (TKIs) are used to treat a variety of cancer types. The current diagnostic tools lack the predictive power to match the right patient with the right TKI. KinaSense is developing technologies that can be used to predict whether a given patient will benefit from a specific TKI.
KinaSense is leveraging its intellectual property to develop assays for in vitro and cell-based kits for measuring TKI efficacy and selectivity. Our unique platform allows measurement of endogenous kinase activity in live cells, bridging the gap between in vitro biochemical and cell-based phenotypic measurements.
KinaSense holds an exclusive license to a technology for detection of tyrosine kinase activity from Purdue Research Foundation.
In vitro and cell-based kinase activity kits for primary or secondary compound library screening
KinaSense is currently performing proof of concept studies for applying its technologies to advanced renal cell carcinoma.
Dr. Ouellette is leading the KinaSense effort through business and product development decisions as the Chief Technology Officer. He holds a Ph.D. in Medicinal Chemistry and Molecular Pharmacology from Purdue University, with specialization in bioassay development, cancer biology, and molecular signaling. Steve has worked extensively with cell-based kinase activity assays using the KinaSense core technology.
KinaSense core technology was invented in Dr. Parker’s lab at Purdue University in the Department of Medicinal Chemistry and Molecular Pharmacology. She is an inventor and has expertise in synthetic chemistry, bioassay design, and proteomics, and is scientific advisor to KinaSense. Laurie is currently Assistant Professor at University of Minnesota in the Department of Biochemistry, Molecular Biology and Biophysics.
Dr. Lipchik is a primary inventor of the KinaSense core technology and a scientific advisor to KinaSense. He holds a Ph.D. from the Department of Medicinal Chemistry and Molecular Pharmacology at Purdue University. Andrew is currently doing post-doctoral research at Stanford University in the lab of Michael Snyder.
KinaSense is a client company of the Purdue Foundry. The Foundry provides business development advice regarding strategy, relations, accounting, and opportunities. The Foundry serves over 15 client companies based on Purdue University developed technology, and is an entrepreneurial hotspot in the Lafayette/West Lafayette, IN region.
Horizon BioAdvance is a biomedical research company in Lafayette, IN. They provide assistance in investor relations, business development, and clinincal strategy for KinaSense. Their medical oncologist is Wael Harb, MD, who has extensive experience in cancer drug clinical trials.